Impact of Vessel Size on Angiographic and Clinical Outcomes of Revascularization With Biolimus-Eluting Stent With Biodegradable Polymer and Sirolimus-Eluting Stent With Durable Polymer. The LEADERS Trial Substudy

JACC: Cardiovascular Interventions

Volumn 2, Issue 9, 2009, Pages 861-870

  Wykrzykowska, Joanna J ^a   Serruys, Patrick W ^a   Onuma, Yoshinobu ^a   de Vries, Ton ^b   van Es, Gerrit Anne ^b   Buszman, Pawel ^c   Linke, Axel ^d   Ischinger, Thomas ^e   Klauss, Volker ^f   Corti, Roberto ^g   Eberli, Franz ^g,l   Wijns, William ^h   Morice, Marie Claude ⁱ   di Mario, Carlo ^j   van Geuns, Robert Jan ^a   Juni, Peter ^k   Windecker, Stephan ^k  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b CARDIALYSIS   (Netherlands)

^c MEDICAL UNIVERSITY OF SILESIA   (Poland)

^d UNIVERSITY OF LEIPZIG HEART CENTER   (Germany)

^e KLINIKUM BOGENHAUSEN   (Germany)

^f LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^g UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^h OLV HOSPITAL   (Belgium)

ⁱ Institut Cardiovasculaire   (France)

^j ROYAL BROMPTON HOSPITAL   (United Kingdom)

^k UNIVERSITY OF BERN   (Switzerland)

^l TRIEMLI HOSPITAL   (Switzerland)

more..

Author keywords

biodegradable polymer; biolimus eluting stent; long lesions; sirolimus eluting stent; small vessels; target vessel revascularization

Indexed keywords

BIOLIMUS; RAPAMYCIN; RAPAMYCIN DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD VESSEL DIAMETER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART MUSCLE REVASCULARIZATION; HUMAN; IN-STENT RESTENOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; STENT THROMBOSIS; SURVIVAL RATE;

ABSORBABLE IMPLANTS; AGED; ANGIOPLASTY, BALLOON, CORONARY; CARDIOVASCULAR AGENTS; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; CORONARY STENOSIS; DRUG-ELUTING STENTS; EUROPE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; POLYMERS; PROPORTIONAL HAZARDS MODELS; PROSTHESIS DESIGN; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SIROLIMUS; THROMBOSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 70349235710     PISSN: 19368798     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcin.2009.05.024     Document Type: Article

References (22)

1. Windecker S., Serruys P.W., Wandel S., et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet 372 (2008) 1163-1173
2. Grube E., and Buellesfeld L. BioMatrix Biolimus A9-eluting coronary stent: a next-generation drug-eluting stent for coronary artery disease. Expert Rev Med Devices 3 (2006) 731-741
3. Mauri L., Orav E.J., Candia S.C., Cutlip D.E., and Kuntz R.E. Robustness of late lumen loss in discriminating drug-eluting stents across variable observational and randomized trials. Circulation 112 (2005) 2833-2839
4. Mauri L., Orav E.J., and Kuntz R.E. Late loss in lumen diameter and binary restenosis for drug-eluting stent comparison. Circulation 111 (2005) 3435-3442
5. Mauri L., Orav E.J., O'Malley A.J., et al. Relationship of late loss in lumen diameter to coronary restenosis in sirolimus-eluting stents. Circulation 111 (2005) 321-327
6. Meier B., Sousa E., Guagliumi G., et al. Sirolimus-eluting coronary stents in small vessels. Am Heart J 151 (2006) 1019.e1-1019.e7
7. Kuntz R.E., Safian R.D., Carrozza J.P., Fishman R.F., Mansour M., and Baim D.S. The importance of acute luminal diameter in determining restenosis after coronary atherectomy or stenting. Circulation 86 (1992) 1827-1835
8. Kuntz R.E., Safian R.D., Levine M.J., Reis G.J., Diver D.J., and Baim D.S. Novel approach to the analysis of restenosis after the use of three new coronary devices. J Am Coll Cardiol 19 (1992) 1493-1499
9. Togni M., Eber S., Widmer J., et al. Impact of vessel size on outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents: a subgroup analysis of the SIRTAX trial. J Am Coll Cardiol 50 (2007) 1123-1131
10. Ellis S.G., Popma J.J., Lasala J.M., et al. Relationship between angiographic late loss and target lesion revascularization after coronary stent implantation: analysis from the TAXUS-IV trial. J Am Coll Cardiol 45 (2005) 1193-1200
11. Regar E., Serruys P.W., Bode C., et al. Angiographic findings of the multicenter Randomized Study With the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent (RAVEL): sirolimus-eluting stents inhibit restenosis irrespective of the vessel size. Circulation 106 (2002) 1949-1956
12. Mauri L., Hsieh W.H., Massaro J.M., Ho K.K., D'Agostino R., and Cutlip D.E. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 356 (2007) 1020-1029
13. Windecker S., Remondino A., Eberli F.R., et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med 353 (2005) 653-662
14. Kastrati A., Mehilli J., von Beckerath N., et al. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA 293 (2005) 165-171
15. Elezi S., Dibra A., Mehilli J., et al. Vessel size and outcome after coronary drug-eluting stent placement: results from a large cohort of patients treated with sirolimus- or paclitaxel-eluting stents. J Am Coll Cardiol 48 (2006) 1304-1309
16. Tanimoto S., Daemen J., Tsuchida K., et al. Two-year clinical outcome after coronary stenting of small vessels using 2.25-mm sirolimus- and paclitaxel-eluting stents: insight into the RESEARCH and T-SEARCH registries. Catheter Cardiovasc Interv 69 (2007) 94-103
17. Pfisterer M., Brunner-La Rocca H.P., Rickenbacher P., et al. Long-term benefit-risk balance of drug-eluting vs. bare-metal stents in daily practice: does stent diameter matter?. Three-year follow-up of BASKET. Eur Heart J 30 (2009) 16-24
18. Joner M., Finn A.V., Farb A., et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 48 (2006) 193-202
19. Hezi-Yamit A., Sullivan C., Wong J., et al. Novel high throughput polymer biocompatibility screening designed for SAR (structure-activity relationship): application for evaluating polymer coatings for cardiovascular drug-eluting stents. Comb Chem High Throughput Screen (2009 Aug 1) [E-pub ahead of print]
20. Serruys P.W., Morice M.C., Kappetein A.P., et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 360 (2009) 961-972
21. Stone G.W., Witzenbichler B., Guagliumi G., et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 358 (2008) 2218-2230
22. Wiviott S.D., Braunwald E., McCabe C.H., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357 (2007) 2001-2015